Department of Bone and Soft Tissue Tumors, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Department of Maxillofacial and Otorhinolaryngological Oncology, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer, Prevention and Therapy, Tianjin Cancer Institute, National Clinical Research Center of Cancer, Tianjin, China.
Front Immunol. 2022 Dec 7;13:1026701. doi: 10.3389/fimmu.2022.1026701. eCollection 2022.
Tumor-infiltrating B cells play a crucial role in the promotion or inhibition of tumor development. However, the role of B cells in osteosarcoma remains largely unknown. The aim of this study was to investigate the effect of B cells on the prognosis and immunity infiltration of osteosarcoma.
Marker genes of B cells were identified based on the single-cell sequencing results of osteosarcoma in the GEO database. The prognostic model was established by the TCGA database and verified by the GEO data. The divergence in immune infiltration between the low-risk and high-risk groups was then compared according to the established prognostic model. Finally, the differential genes in the low-risk and high-risk groups were enriched and analyzed.
A total of 261 B cell marker genes was obtained by single-cell sequencing and a prognostic model of 4 B cell marker genes was established based on TCGA data. The model was found to have a good prediction performance in the TCGA and GEO data. A remarkable difference in immune infiltration between the low-risk and high-risk groups was also observed. The obtained results were verified by enrichment analysis.
In summary, a prognostic model with good predictive performance was established that revealed the indispensable role of B cells in the development of osteosarcoma. This model also provides a predictive index and a novel therapeutic target for immunotherapy for clinical patients.
肿瘤浸润 B 细胞在促进或抑制肿瘤发展方面发挥着关键作用。然而,B 细胞在骨肉瘤中的作用在很大程度上仍不清楚。本研究旨在探讨 B 细胞对骨肉瘤预后和免疫浸润的影响。
基于 GEO 数据库中骨肉瘤的单细胞测序结果,确定 B 细胞的标记基因。利用 TCGA 数据库建立预后模型,并通过 GEO 数据进行验证。然后根据建立的预后模型比较低风险组和高风险组之间免疫浸润的差异。最后,对低风险组和高风险组之间的差异基因进行富集分析。
通过单细胞测序获得了 261 个 B 细胞标记基因,并基于 TCGA 数据建立了一个由 4 个 B 细胞标记基因组成的预后模型。该模型在 TCGA 和 GEO 数据中均具有良好的预测性能。低风险组和高风险组之间的免疫浸润也存在显著差异。通过富集分析验证了这些结果。
总之,建立了一个具有良好预测性能的预后模型,揭示了 B 细胞在骨肉瘤发生发展中的不可或缺的作用。该模型还为临床患者的免疫治疗提供了一个预测指标和一个新的治疗靶点。